Bioventus Inc.
BVS- Exchange
- Nasdaq
- Industry
- Surgical & Medical Instruments & Apparatus
- SEC CIK
- 0001665988
No open-market purchases or sales by Bioventus Inc. insiders were filed in the last 90 days; 156 institutions reported holding it in 13F filings for Q2 2026, worth $509.4M in total; no superinvestor holds it.
Open-market trades, last 90 days
Open-market purchases (P) and sales (S) by Bioventus Inc. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.
- Open-market buys
- 0 filings
- Open-market sells
- 0 filings
- Insiders trading
- 0
- Net value
- $0
- Purchases minus sales
Insider roster
Directors, officers and 10% owners who have filed a Form 4 for Bioventus Inc., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.
| Name | Title | Last reported holding | Last filing | Filings, past year |
|---|---|---|---|---|
| Sutter Martin P | Director, 10% Owner | 117,523 | Jun 4, 2026 | 1 |
| Hawkins William A | Director | 297,640 | Jun 4, 2026 | 1 |
| Nohra Guy P | Director | 148,892 | Jun 4, 2026 | 2 |
| Stalnecker Susan M | Director | 138,239 | Jun 4, 2026 | 1 |
| Neels Guido J | Director | 117,523 | Jun 4, 2026 | 1 |
| Bartholdson John A. | Director, 10% Owner | 111,902 | Jun 4, 2026 | 1 |
| Beyer Pat | Director | 108,718 | Jun 4, 2026 | 1 |
| Cowdy Philip G. | Director | 43,982 | Jun 4, 2026 | 3 |
| Ladone Mary Kay | Director | 111,263 | Jun 4, 2026 | 1 |
| McMurry-Heath Michelle | Director | 77,279 | Jun 4, 2026 | 3 |
| Church Katrina J | SVP & Chief Compliance Officer | 64,164 | Apr 14, 2026 | 3 |
| D'Adamio Anthony | SVP & General Counsel | 153,655 | Apr 14, 2026 | 3 |
| Singleton Mark Leonard | SVP & CFO | 177,333 | Apr 14, 2026 | 4 |
| Claypoole Robert E | President and CEO | 135,944 | Mar 17, 2026 | 2 |
| Bihl Anthony P III | Interim CEO | 26,595Indirect | Aug 22, 2023 | 0 |
| Michas Alexis P | 10% Owner | 6,833,857Indirect | Aug 15, 2023 | 0 |
| Juniper Investment Company, LLC | 10% Owner | 6,833,857Indirect | Aug 15, 2023 | 0 |
| Reali Kenneth Michael | Fmr. CEO and Director | 30,085 | Apr 21, 2023 | 0 |
| Pavesio Alessandra | Fmr. SVP & Chief Science Off. | 148,309 | Apr 21, 2023 | 0 |
| Nosenzo John | Fmr. Chief Commercial Officer | 87,148 | Apr 21, 2023 | 0 |
| Vizirgianakis Stavros G. | Director | 2,781,888 | Jun 22, 2022 | 0 |
| Anglum Gregory O. | SVP & CFO | 55,013 | Feb 15, 2022 | 0 |
Insider trades
Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Feb 16, 2022 (view filing) | Feb 14 | 2 days | Pavesio AlessandraSVP & Chief Science Officer | SSaleClass A Common Stock | −433 | $11.99 | −$5.19K | −0.4%119.8K after | |
| Feb 15, 2022 (view filing) | Feb 14 | 1 day | D'Adamio AnthonySVP & General Counsel | SSaleClass A Common Stock | −1.29K | $11.99 | −$15.5K | −6.5%18.7K after | |
| Feb 15, 2022 (view filing) | Feb 14 | 1 day | Anglum Gregory O.SVP & CFO | SSaleClass A Common Stock | −1.29K | $11.99 | −$15.5K | −2.3%55.0K after | |
| Feb 15, 2022 (view filing) | Feb 14 | 1 day | Nosenzo JohnChief Commercial Officer | SSaleClass A Common Stock | −534 | $11.99 | −$6.40K | −1.2%43.4K after | |
| Sep 10, 2021 (view filing) | Sep 9 | 1 day | Reali Kenneth MichaelCHIEF EXECUTIVE OFFICER | PPurchaseClass A Common Stock | +1.80K | $14.81 | +$26.7K | +19.2%11.2K after |